Deep DiveApril 15, 2026·9 min read
The State of AI in Drug Discovery: 2026 Landscape
From hype cycle to clinical validation — the deals, data, and companies defining the new era
Read moreResearch
Analysis & Intelligence
Long-form analysis of the technologies, deals, and clinical data shaping biotech and drug discovery.
Deep DiveApril 12, 2026·10 min read
Protein Structure Prediction: From AlphaFold to Boltz-2
How open-source challengers are reshaping structural biology — and why binding affinity changes everything
Read moreDeep DiveApril 10, 2026·9 min read
PROTAC Renaissance: How AI is Reviving Protein Degradation
30 clinical candidates, a pending FDA approval, and a new generation of AI-designed degraders
Read moreDeep DiveApril 8, 2026·9 min read
The ADC Gold Rush: 2026 Deal Landscape
A $15 billion market, record-breaking deals, and the race to build better payloads
Read moreDeep DiveApril 5, 2026·10 min read
CRISPR Goes Clinical: Base Editing and Prime Editing Results
From Casgevy to PM359 — the next-generation editors are entering human trials with remarkable early data
Read moreBenchmark2026-04-16·8 min read
AlphaFold2 vs Boltz-1 vs Chai-1: Structure Prediction Compared (2026)
The protein structure prediction landscape shifted dramatically in 2025-2026. AlphaFold2 remains the production workhorse for single-chain prediction, but the '…
Read moreBenchmark2026-04-16·8 min read
DiffDock vs GNINA vs AutoDock Vina: Molecular Docking Compared (2026)
Molecular docking is the workhorse of structure-based drug discovery. AutoDock Vina has been the default open-source tool for over a decade. GNINA augmented Vin…
Read moreBenchmark2026-04-16·8 min read
ADMET-AI vs ADMETlab 3.0 vs SwissADME: ADMET Prediction Compared (2026)
Every drug candidate needs ADMET profiling — absorption, distribution, metabolism, excretion, and toxicity prediction. SwissADME has been the go-to free tool fo…
Read moreBenchmark2026-04-16·8 min read
RFdiffusion vs ProteinMPNN vs BindCraft: Protein Design Compared (2026)
De novo protein design has gone from science fiction to routine workflow in three years. RFdiffusion generates novel protein backbones, ProteinMPNN designs sequ…
Read moreBenchmark2026-04-16·8 min read
DiffAb vs RFantibody vs AntiFold: Antibody Design Compared (2026)
AI antibody design reached a milestone in 2025 when RFantibody demonstrated atomically accurate de novo antibody design confirmed by cryo-EM (Nature 2025). Toge…
Read moreBenchmark2026-04-16·8 min read
Boltz-2 vs AlphaFold3 vs Chai-1: Next-Gen Structure + Affinity Prediction (2026)
AlphaFold3 set the bar for biomolecular complex prediction in 2024, but its restrictive license and closed weights left a gap. Boltz-2 (MIT, June 2025) fills it…
Read moreBenchmark2026-04-16·8 min read
ESM-2 vs ProGen2 vs EvoDiff: Protein Language Models & Generation (2026)
Protein language models are the foundation of modern computational biology. ESM-2 (Meta) provides rich learned representations used for everything from structur…
Read moreBenchmark2026-04-16·8 min read
AiZynthFinder vs ASKCOS vs RetroTRAE: Retrosynthesis Planning (2026)
Retrosynthesis planning — working backward from a target molecule to purchasable starting materials — is a core challenge in medicinal chemistry. AiZynthFinder …
Read moreBenchmark2026-04-17·8 min read
GROMACS vs OpenMM vs AMBER: Molecular Dynamics Engines (2026)
GROMACS, OpenMM, and AMBER are the three dominant engines for biomolecular molecular dynamics. GROMACS (University of Groningen/KTH) is the speed king on both C…
Read moreBenchmark2026-04-17·8 min read
Open Targets vs DisGeNET vs PharmGKB: Target Discovery Databases (2026)
Target identification and validation is the first critical decision in drug discovery — pick the wrong target and years of effort are wasted. Open Targets (Well…
Read moreBenchmark2026-04-17·8 min read
REINVENT4 vs PocketFlow vs MolGPT: Small Molecule Generation (2026)
Generative molecular design has matured into three distinct paradigms. REINVENT4 (AstraZeneca) uses reinforcement learning to steer RNN/transformer generators t…
Read moreBenchmark2026-04-17·8 min read
AlphaFold3 vs Boltz-1 vs Chai-1 vs Protenix: AF3-Class Shootout (2026)
AlphaFold3 (DeepMind, May 2024) set a new bar for biomolecular complex prediction — proteins, ligands, nucleic acids, ions, all in one shot. But its restrictive…
Read moreBenchmark2026-04-17·8 min read
scGPT vs CellTypist vs scBERT: Single-Cell Foundation Models (2026)
Single-cell RNA sequencing generates massive datasets requiring automated cell type annotation, and three distinct approaches have emerged. scGPT (University of…
Read moreScience Gap2026·5 min read
AI Protein Degraders for Neurodegeneration
Tau and alpha-synuclein aggregates drive Alzheimer's and Parkinson's diseases, yet no approved therapy can selectively degrade these proteins. Traditional small…
Read moreScience Gap2026·5 min read
AI-Designed Antibodies for Refractory Autoimmune Disease
Patients with refractory lupus (SLE) and inflammatory bowel disease (IBD) often fail existing biologics. Multi-target approaches are needed but designing bispec…
Read moreScience Gap2026·5 min read
Computational Retrosynthesis for Natural Product Total Synthesis
Natural products remain a premier source of drug leads, but their structural complexity makes total synthesis extremely challenging—often requiring 20–40 steps …
Read moreScience Gap2026·5 min read
AI-Optimized ADC Linker Design
Antibody-drug conjugates (ADCs) are transforming oncology, but linker instability causes off-target toxicity and limits therapeutic windows. Current linker desi…
Read moreScience Gap2026·5 min read
Foundation Models for Single-Cell Drug Response Prediction
Drug response varies dramatically across cell types and patient populations. Current bulk-level assays mask critical heterogeneity. Predicting how individual ce…
Read moreScience Gap2026·5 min read
AI-Guided Radiopharmaceutical Targeting
Radiopharmaceutical theranostics are revolutionizing oncology (Lu-177 PSMA for prostate cancer), but target identification for new tumor types is slow, dosimetr…
Read moreScience Gap2026·5 min read
Generative Chemistry for CNS-Penetrant Molecules
Over 98% of small molecules and nearly 100% of biologics fail to cross the blood-brain barrier (BBB). CNS disorders represent ~$80B in unmet therapeutic need, y…
Read moreScience Gap2026·5 min read
AI Clinical Trial Design for Rare Diseases
Over 7,000 rare diseases affect 300M+ people globally, yet 95% have no approved treatment. Traditional clinical trials require large patient cohorts that simply…
Read moreScience Gap2026·5 min read
Computational Prediction of Drug-Drug Interactions for Combination Therapies
Combination therapies are the standard of care in oncology, infectious disease, and increasingly autoimmune disease, yet predicting drug-drug interactions (DDIs…
Read moreScience Gap2026·5 min read
AI for Predicting Immunogenicity of Biologic Therapeutics
Anti-drug antibodies (ADAs) affect up to 90% of patients on certain biologics, reducing efficacy and causing adverse reactions. Immunogenicity is one of the top…
Read more